Fluphenazine Decanoate

CHEMBL1200854 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

591.8 g/mol

LogP

9.0

Phase

4

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

الوزن الجزيئي

591,8000 g/mol

LogP

9,00

TPSA

61,30 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Schizophrenia Psoriasis

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Molecular Formula

C32H44F3N3O2S

HBD / HBA

- / 9

الروابط القابلة للدوران

16

الذرات الثقيلة

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200854. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3388. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Fluphenazine Decanoate على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C32H44F3N3O2S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.